Bevacizumab for Recurrent Glioma - A Personal View
Pp. 133-139 (7)
Treatment of recurrent glioma remains a therapeutic challenge. Unprecedented high response rates associated with rapid clinical improvement have been observed. Despite the absence of definitive data and while definitive trial has not even been started, regulatory approval was requested. And while the United States Food and Drug Administration granted accelerated approval based on 2 small uncontrolled phase II trials, the European Medicines Agency rejected the application.
Centre Hospitalier Universitaire Vaudois and University of Lausanne, Departments of Oncology and Neurosurgery.